Literature DB >> 22614805

TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation.

Xiao Yan Ni1, Hua Xiu Sui, Yao Liu, Shi Zhong Ke, Yi Nan Wang, Feng Guang Gao.   

Abstract

The effects of TGF-β on dendritic cells (DCs) on the tumor microenvironment are not well understood. We report, here, the establishment of an in vitro lung cancer microenvironment by co-incubation of seminaphtharhodafluor (SNARF) labeled Lewis lung cancer (LLC) cells, carboxyfluorescein succinimidyl ester (CFSE) labeled fibroblasts and 4-chloromethyl-7-hydroxycoumarin (CMHC) labeled DCs. Raw 264.7, EL4 and NCI-H446 cells were able to synthesize TGF-β which was determined by flow cyto-metry and western blotting, respectively. Furthermore, TGF-β efficiently increased regulatory T-cell (Treg) expansion and upregulated DC B7H1 and GITRL expression. TGF-β and the co-incubation of LLC cells, fibroblasts with DCs could augment the expression of B7H1 and GITRL molecules of DCs. The data presented here indicate that the B7H1 and GITRL molecules may play an important role in TGF-β-induced Treg expansion of lung cancer microenvironment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614805     DOI: 10.3892/or.2012.1822

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  29 in total

Review 1.  Mechanisms Controlling PD-L1 Expression in Cancer.

Authors:  Jong-Ho Cha; Li-Chuan Chan; Chia-Wei Li; Jennifer L Hsu; Mien-Chie Hung
Journal:  Mol Cell       Date:  2019-10-24       Impact factor: 17.970

2.  Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Authors:  Galina V Shurin; Yang Ma; Michael R Shurin
Journal:  Cancer Microenviron       Date:  2013-06-09

Review 3.  Regulation and Function of the PD-L1 Checkpoint.

Authors:  Chong Sun; Riccardo Mezzadra; Ton N Schumacher
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

Review 4.  Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors:  Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

5.  Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.

Authors:  Iwona Kwiecień; Elżbieta Rutkowska; Agata Raniszewska; Rafał Sokołowski; Joanna Bednarek; Karina Jahnz-Różyk; Piotr Rzepecki; Joanna Domagała-Kulawik
Journal:  Cancer Immunol Immunother       Date:  2022-03-07       Impact factor: 6.630

Review 6.  Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Authors:  Mariacarmela Santarpia; María González-Cao; Santiago Viteri; Niki Karachaliou; Giuseppe Altavilla; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2015-12

Review 7.  Autoimmunity as a double agent in tumor killing and cancer promotion.

Authors:  Kevin H Toomer; Zhibin Chen
Journal:  Front Immunol       Date:  2014-03-18       Impact factor: 7.561

8.  Increased antigen presentation but impaired T cells priming after upregulation of interferon-beta induced by lipopolysaccharides is mediated by upregulation of B7H1 and GITRL.

Authors:  Fang Wang; Yan Yan Wang; Juan Li; Xiang You; Xin Hui Qiu; Yi Nan Wang; Feng Guang Gao
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

9.  PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.

Authors:  Zhenhua Li; Pengzhi Dong; Meijing Ren; Yawen Song; Xiaolong Qian; Yiling Yang; Shuai Li; Xinmin Zhang; Fangfang Liu
Journal:  J Cancer       Date:  2016-04-10       Impact factor: 4.207

Review 10.  Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Authors:  Marlies E Heuvers; Joachim G Aerts; Robin Cornelissen; Harry Groen; Henk C Hoogsteden; Joost P Hegmans
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.